; (ii) in paragraph (2), by inserting or xylazine for illicit uses under section 424 after controlled substance ; and (iii) in paragraph (3), by inserting or xylazine for illicit uses under section 424 after controlled substance ; and (B) in subsection (b)(5), by inserting or the unlawful distribution of xylazine for illicit uses under section 424 after schedule III . (b) Illicit use and distribution Part D of the Controlled Substances Act ( 21 U.S.C. 401 et seq. ) is amended by adding at the end the following: 424. Illicit use and distribution of xylazine (a) Illicit use It is unlawful for any person to engage in any of the following illicit uses of xylazine: (1) Any use in the human species. (2) Any use that is not a licit use. (b) Licit use Licit use of xylazine means— (1) any administration to nonhuman species— (A) of a drug containing xylazine that has been approved by the Secretary of Health and Human Services under section 512 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360b ); or (B) that is permissible under section 512(a)(4) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360b(a)(4) ); (2) the manufacturing, importation, or use of xylazine as an active pharmaceutical ingredient for manufacturing an animal drug approved under section 512 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360b ) or issued an investigation use exemption under subsection (j) of such section 512; (3) the manufacturing, importation, or use of a xylazine bulk chemical for pharmaceutical compounding by licensed pharmacists or veterinarians; or (4) another use approved or permissible under the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 301 et seq. ). . 5. Arcos tracking Section 307(i) of the Controlled Substances Act ( 21 U.S.C. 827 ) is amended— (1) in the matter preceding paragraph (1)— (A) by inserting or xylazine after gamma hydroxybutyric acid ; (B) by inserting or 512 after section 505 ; and (C) by inserting respectively, after the Federal Food, Drug, and Cosmetic Act,